ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met

Damghani, Tahereh; Moosavi, Fatemeh; Khoshneviszadeh, Mehdi; Mortazavi, Motahareh; Pirhadi, Somayeh; Kayani, Zahra; Saso, Luciano; Edraki, Najmeh*; Firuzi, Omidreza*
Scientific Reports2021-2-11DOI: 10.1038/s41598-021-83069-4
31被引4阅读
引用收藏
分享

摘要

Aberrant activation of c-Met signalling plays a prominent role in cancer development and progression. A series of 12 imidazo [1,2-alpha] pyridine derivatives bearing 1,2,3-triazole moiety were designed, synthesized and evaluated for c-Met inhibitory potential and anticancer effect. The inhibitory activity of all synthesized compounds against c-Met kinase was evaluated by a homogeneous time-resolved fluorescence (HTRF) assay at the concentration range of 5-25 mu M. Derivatives 6d, 6e and 6f bearing methyl, tertiary butyl and dichloro-phenyl moieties on the triazole ring, respectively, were the compounds with the highest potential. They significantly inhibited c-Met by 55.3, 53.0 and 51.3%, respectively, at the concentration of 25 mu M. Synthetic compounds showed antiproliferative effects against lung (EBC-1) and pancreatic cancer cells (AsPc-1, Suit-2 and Mia-PaCa-2) expressing different levels of c-Met, with IC50 values as low as 3.0 mu M measured by sulforhodamine B assay. Active derivatives significantly blocked c-Met phosphorylation, inhibited cell growth in three-dimensional spheroid cultures and also induced apoptosis as revealed by Annexin V/propidium iodide flow cytometric assay in AsPc-1 cells. They also inhibited PDGFRA and FLT3 at 25 mu M among a panel of 16 kinases. Molecular docking and dynamics simulation studies corroborated the experimental findings and revealed possible binding modes of the select derivatives with target receptor tyrosine kinases. The results of this study show that some imidazopyridine derivatives bearing 1,2,3-triazole moiety could be promising molecularly targeted anticancer agents against lung and pancreatic cancers.

学科与关键词

关键词
CABOZANTINIB XL184ANTITUMOR-ACTIVITYGENETIC ALGORITHMVEGFR2 INHIBITORDISCOVERYDESIGNMOIETYBREAKTHROUGHCHALLENGESPROGRESS
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Scientific Reports
发表日期
2021-02-11
卷期
第 11 卷, 第 1 期
页码
3644
DOI
10.1038/s41598-021-83069-4
语言
ENGLISH
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
Shiraz University of Medical Sciences [1396-01-05-15365, 1396-01-106-15688]; National Institute for Medical Research Development (NIMAD) [957652]

作者

  • D

    Damghani, Tahereh (第一作者)

  • M

    Moosavi, Fatemeh

查看全部 9 位作者收起作者
  • K

    Khoshneviszadeh, Mehdi

  • M

    Mortazavi, Motahareh

  • P

    Pirhadi, Somayeh

  • K

    Kayani, Zahra

  • S

    Saso, Luciano

  • E

    Edraki, Najmeh (通讯)

  • F

    Firuzi, Omidreza (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417